KWM
INTS icon

KMT Wealth Management’s Intensity Therapeutics INTS Stock Holding History

KMT Wealth Management’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.04M Buy
+496,493
New +$2.33M 1.72% 10

Other funds holding INTS

SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return

KMT Wealth Management's INTS Position: Q2 2026 in Review

KMT Wealth Management opened a new position in Intensity Therapeutics (INTS) in Q2 2026: 496,493 shares worth $2.04M. The stake represents 1.72% of the portfolio and ranks #10 among its holdings.

14 funds tracked by Wall St. Rank hold INTS as of Q2 2026.

  • KMT Wealth Management held 496,493 shares of Intensity Therapeutics worth $2.04M as of Q2 2026.
  • Intensity Therapeutics was a new KMT Wealth Management position in Q2 2026.
  • Intensity Therapeutics made up 1.72% of KMT Wealth Management's portfolio in Q2 2026, its #10 holding.
  • 14 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2026.

Based on KMT Wealth Management's 13F filing for Q2 2026, filed 5 Aug 2026.